knowledge -WSS

knowledge

author：comprehensive 2025-09-14 18:26:59 - browse：51597

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Decaf coffee targeted by food safety group under obscure FDA rule

focus

WSS

The Readout: Lenmeldy, GLP

Patient advocates debate FDA's accelerated approval process

Diversifying clinical trials isn't enough to close racial gaps: study

Readout Newsletter: What happened with Sarepta's Duchenne data

WHO may add ‘noma' to its list of neglected tropical diseases

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

knowledge

hotspot

Activists slam private health insurers over coverage restrictions

Abortion pill Supreme Court ruling could impact entire drug industry

How one medical school became remarkably diverse

Meta's Zuckerberg and Chan on track to put $50 billion into science

In Memoriam: Notable people who died in 2023

Paying for Covid pills will soon shift to insurers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Merck, Vertex, and Viking updates

Tori Bowie and the unacceptable rates of Black maternal death

Abortion pill Supreme Court ruling could impact entire drug industry

explore

Maker of FluMist seeks to allow at

WHO may add ‘noma' to its list of neglected tropical diseases

Chimpanzees, like humans and whales, get menopause: Study

Telehealth options flood the market as retailers push virtual care

Why Sanofi got shellacked over its spinoff

Cassava reveals details — and problems — with Alzheimer's study

focus

focus

focus

hotspot